Add like
Add dislike
Add to saved papers

Effects of a JAK inhibitor, AG490, on proliferation and apoptosis of human nasopharyngeal carcinoma cell line CNE-2Z.

BACKGROUND AND OBJECTIVE: Abnormal activation of Janus kinas/signal transducer and activator of transcription 3 (JAK-STAT3) signaling pathway is closely related to malignant transformation of cells. This study was to investigate the effects of a JAK inhibitor, AG490, on the proliferation, apoptosis, and expressions of apoptosis-related survivin and Mcl-1 genes, thus to explore the role of JAK-STAT3 signaling pathway in the regulation of cell apoptosis in nasopharyngeal carcinoma (NPC) cell line CNE-2Z.

METHODS: CNE-2Z cells were treated with different doses of AG490. The cell proliferation was measured using MTT array. Cell apoptosis was assessed by flow cytometry (FCM) and Hoechst33342 fluorescence staining. The mRNA levels of STAT3, survivin and Mcl-1 were detected by reverse transcription-polymerase chain reaction (RT-PCR). The protein contents of STAT3, phosphoralated STAT3 (p-STAT3), survivin and Mcl-1 were measured by western blot.

RESULTS: The inhibition rates of CNE-2Z cell proliferation by 100 micromol/L AG490 were 37.95% and 52.99% at 24 and 48 h after treatment. After incubation with 50 micromol/L and 100 micromol/L AG490 for 24 h, the apoptotic rates of CNE-2Z cells were increased from 1.37% to 9.30% and 9.00%, respectively (p < 0.01); typical changes in apoptotic morphology were observed under fluorescence microscopy; moreover, activation of STAT3 was inhibited, mRNA and protein levels of Mcl-1 and survivin were down-regulated.

CONCLUSION: Blocking of JAK-STAT3 signaling pathway in CNE-2Z cells could remarkably inhibit cell proliferation and inactivate STAT3, as well as promote cell apoptosis by down-regulating Mcl-1 and survivin.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app